Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 94.1% |
| 2 | Technology | 1.55% |
| 3 | Consumer Discretionary | 0.95% |
| 4 | Financials | 0.77% |
| 5 | Healthcare | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2426
PUT
Synchrony
SYF
$25.9B
| $10.9M | ﹤0.01% |
205,000
-90,800
| -31% | -$5.62M |
|
2427
Recursion Pharmaceuticals
RXRX
$1.82B
| $10.8M | ﹤0.01% |
2,049,611
+382,622
| +23% | +$2.79M |
|
2428
PUT
Hertz
HTZ
$759M
| $10.8M | ﹤0.01% |
2,746,900
+434,100
| +19% | +$1.74M |
|
2429
CALL
Gold Fields
GFI
$42B
| $10.8M | ﹤0.01% |
489,300
-159,000
| -25% | -$2.91M |
|
2430
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$215M
| $10.8M | ﹤0.01% |
215,000
-209,200
| -49% | -$9.51M |
|
2431
PUT
Cytokinetics
CYTK
$9.99B
| $10.8M | ﹤0.01% |
268,200
+22,700
| +9% | +$1.04M |
|
2432
Northrop Grumman
NOC
$77.3B
| $10.8M | ﹤0.01% |
21,041
-45,171
| -68% | -$21.6M |
|
|
BECN
2433
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $10.8M | ﹤0.01% |
86,969
-31,142
| -26% | -$3.63M |
|
2434
PUT
Coupang
CPNG
$30B
| $10.8M | ﹤0.01% |
490,500
+118,900
| +32% | +$2.76M |
|
2435
M&T Bank
MTB
$34.5B
| $10.8M | ﹤0.01% |
60,165
-24,379
| -29% | -$4.62M |
|
2436
NuScale Power
SMR
$3.92B
| $10.8M | ﹤0.01% |
759,446
+467,037
| +160% | +$9.44M |
|
2437
CALL
Halozyme
HALO
$11.9B
| $10.7M | ﹤0.01% |
168,400
-81,800
| -33% | -$4.75M |
|
2438
Chord Energy
CHRD
$7.96B
| $10.7M | ﹤0.01% |
95,278
-4,521
| -5% | -$514K |
|
2439
PUT
Genuine Parts
GPC
$18.7B
| $10.7M | ﹤0.01% |
90,100
+2,800
| +3% | +$337K |
|
|
NVEE
2440
DELISTED
NV5 Global
NVEE
| $10.7M | ﹤0.01% |
556,809
+517,740
| +1,325% | +$9.48M |
|
2441
CALL
ARK Genomic Revolution ETF
ARKG
$1.92B
| $10.7M | ﹤0.01% |
516,500
-787,500
| -60% | -$19.8M |
|
2442
PUT
Trimble
TRMB
$14.3B
| $10.7M | ﹤0.01% |
163,300
+19,400
| +13% | +$1.39M |
|
2443
PUT
Joby Aviation
JOBY
$6.96B
| $10.7M | ﹤0.01% |
1,780,100
-478,900
| -21% | -$3.59M |
|
2444
PUT
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$15B
| $10.7M | ﹤0.01% |
118,000
-33,800
| -22% | -$3.06M |
|
2445
PUT
Sarepta Therapeutics
SRPT
$2.3B
| $10.7M | ﹤0.01% |
167,400
-213,800
| -56% | -$22.5M |
|
|
HUYA
2446
PUT
Huya Inc
HUYA
$496M
| $10.7M | ﹤0.01% |
3,327,500
+3,242,500
| +3,815% | +$11.7M |
|
2447
PUT
Cincinnati Financial
CINF
$26.4B
| $10.7M | ﹤0.01% |
72,300
+42,000
| +139% | +$5.91M |
|
2448
Nextpower Inc. Common Stock
NXT
$13.1B
| $10.7M | ﹤0.01% |
253,409
+61,904
| +32% | +$2.75M |
|
2449
PUT
Onto Innovation
ONTO
$17.3B
| $10.7M | ﹤0.01% |
88,000
+32,500
| +59% | +$5.47M |
|
2450
CALL
Solventum
SOLV
$15.5B
| $10.7M | ﹤0.01% |
140,400
+8,100
| +6% | +$603K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass's Q1 2025 filing shows 1,775 new, 5,712 increased, 4,842 reduced and 1,482 closed positions. Its largest new stake was Brookfield Asset Management: 1,775,684 shares worth $86M. The largest sale was Invesco QQQ Trust, an estimated $1.25B.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.